We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Incidence And Risk Factors Of Contrast Nephropathy After Tace In Patients With Liver Cancer And Chronic Kidney Disease.
- Authors
Kun-Kun Cao; Ning Ding; Xiao-Wei Li; Jia-Ming Zhong; Jian Zhai; Zeng-Qiang Qu; Xiao-Li Zhang; Cao, Kun-Kun; Ding, Ning; Li, Xiao-We; Zhong, Jia-Ming; Zhai, Jian; Qu, Zeng-Qiang; Zhang, Xiao-Li
- Abstract
<bold>Purpose: </bold>Incidence of contrast induced nephropathy (CIN) and related risk factors in patients with liver cancer and chronic kidney disease after trans-catheter arterial chemoembolization (TACE) is higher. The purpose of this study was to investigate the feasibility and safety of TACE therapy in such patients.<bold>Methods: </bold>A retrospective analysis was performed on 103 patients with liver cancer and chronic kidney disease who underwent TACE treatments. TACE was performed according to Seldinger's technique of arterial embolization with minor modifications. Based on CIN diagnostic criteria, patients were divided into non-CIN (n=89) and CIN (n=14) groups. Multiple clinical parameters were assessed for the two groups after TACE. Serum creatinine levels were measured 48-72 h after TACE.<bold>Results: </bold>Tumor size (>5 cm), TACE frequency, contrast agent dosage, solitary kidney, volume of iodized oil used in the TACE (ml) and urea levels were significantly higher in CIN group in comparison with the non-CIN group, while serum albumin and haemoglobin levels were significantly lower. Multivariate logistic regression analysis confirmed that the volume of iodized oil and TACE frequency were significantly positively correlated, and serum albumin level was negatively correlated in the CIN group.<bold>Conclusion: </bold>Volume of iodized oil, TACE frequency and low serum albumin levels were found to be independent risk factors for CIN after TACE. Thus, it is safe and feasible for hepatocellular carcinoma patients with chronic kidney disease to receive TACE treatment, but adverse events management after TACE needs to be addressed.
- Subjects
RENAL cancer; CHRONIC kidney failure; CONTRAST induced nephropathy; LIVER cancer; CONTRAST media; HEPATOCELLULAR carcinoma; THERAPEUTIC embolization; CHRONIC kidney failure complications; TREATMENT of chronic kidney failure; LIVER tumors; CHEMOEMBOLIZATION; RETROSPECTIVE studies; DISEASE incidence
- Publication
Clinical & Investigative Medicine, 2021, Vol 44, Issue 3, pE19
- ISSN
0147-958X
- Publication type
journal article
- DOI
10.25011/cim.v44i3.36961